The Complicated Relationship Between Obstructive Sleep Apnea and Inflammation Biomarkers
Zu‐Hua Gao,Ruyu Yuan,Kuan‐Yu Chen,Guoqing Li
DOI: https://doi.org/10.1111/j.1600-0404.2011.01632.x
2012-01-01
Acta Neurologica Scandinavica
Abstract:Dear Editor It was with a great interest that we have read the article entitled ‘Obstructive sleep apnea and biomarkers of inflammation in ischemic stroke’ by Medeiros et al. (1) published recently in this journal. After reading the article, we benefited a lot from it. In recent years, our institute has been studying the relationship between hypertension, stroke, coronary heart disease, and sleep apnea. Medeiros et al. encouraged us greatly. We would like to share our opinions about the study. The following suggestions are necessary to be considered. Obstructive sleep apnea syndrome (OSAS) is a sleep disorder characterized by recurrent episodes of oxygen desaturation during sleep, representing an independent risk factor for cardiovascular disease, such as stroke, myocardial infarction, congestive heart failure, and resistant hypertension. Studies have suggested a strong bidirectional association between OSAS and metabolic syndrome (MS) (2). The prevalence of OSAS and MS is increasing worldwide, in part linked to epidemic of obesity. The study (3) demonstrated that obese patients with OSAS patients may have an increased rate of MS, but body mass index (BMI) did not adequately describe regional (central) adiposity. The related findings suggested that abdominal obesity, representing abundant mesenteric fat tissue susceptible to hypoxic stress, reduction of visceral fat accumulation may combat OSAS-related atherosclerotic cardiovascular diseases in abdominal obesity (4).The waist circumference and waist–hip ratio seem to be better indicators of all-cause mortality than BMI (5). Atherosclerosis was no longer considered a disorder of lipid accumulation, but a disease process characterized by the dynamic interaction between endothelial dysfunction, subendothelial dysfunction, and inflammation. Prospective epidemiological studies have unequivocally demonstrated increased vascular risk in individuals with elevated levels of cytokines such as interleukin-6 (IL-6). Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease. Inflammatory markers, in particular IL-6 and C-reactive protein, were more strongly associated with risk of fatal vascular events than non-fatal vascular events (6). So, the study should pay more attention to the coronary heart disease. Rupture of unstable atherosclerotic plaques is the pathological substrate for acute ischemic events. Early after stroke and transient ischemic attack, plaques revealed an unstable phenotype. After stroke, changes in IL-6 and IL-8 preceded the decrease of macrophages. These temporal phenotypic plaque alterations should be taken into account for biomarker and therapeutic target validation studies using human atherosclerotic plaques (7). Statins has dramatically reduced morbidity and mortality in patients with established cardiovascular disease. The benefit in reducing cardiovascular risk with statins has been attributed both to cholesterol lowering and pleiotropic effects. Statin therapy reduced inflammatory markers in a largely low-density lipoprotein (LDL)-independent manner, and the ‘anti-inflammatory’ properties of these agents have been suggested as a potential mechanism beyond LDL reduction for the efficacy of these agents. At last, even, the consumption of some typical Mediterranean foods was associated with lower serum concentrations of inflammatory markers especially those related to endothelial function, in subjects with high cardiovascular risk living in a Mediterranean country (8).